Healthcare Industry News: histone deacetylase
News Release - January 28, 2008
Gloucester Pharmaceuticals Announces New Senior Management TeamAlan Colowick, M.D., M.P.H. named Chief Executive Officer Jean Nichols, Ph.D., promoted to President & COO
Don Hayden appointed Chairman of the Board
CAMBRIDGE, Mass.--(HSMN NewsFeed)--Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that it has appointed Alan Colowick, M.D. M.P.H. as Chief Executive Officer and as a member of the company’s Board of Directors. The company also announced that Jean Nichols, Ph.D. has been promoted to President and Chief Operating Officer. Dr. Nichols previously served as Executive Vice President and Chief Scientific Officer. In addition, Donald Hayden, formerly Executive Vice President and President, Americas, at Bristol-Myers Squibb Company, has been named Chairman of Gloucester’s Board of Directors.
“We are very excited that Alan has joined Gloucester as CEO,” stated Mr. Hayden, Gloucester’s incoming Chairman. “Alan’s substantial clinical, regulatory and commercial experience in oncology will be of extraordinary value to Gloucester as our lead product, Romidepsin, advances toward an NDA filing in cutaneous T-cell lymphoma and continues to progress in our ongoing pivotal study in peripheral T-cell lymphoma as well as our other ongoing clinical studies.”
Hayden further commented, “We are also pleased to promote Jean Nichols to President and COO. Jean has been an integral part of Gloucester’s success to date and I look forward to working closely with Jean in her expanded role.”
“I am excited to join Gloucester and to have the opportunity to lead the development and commercial strategy for a drug as promising as Romidepsin,” said Dr. Colowick. “Gloucester is poised to achieve several significant clinical and regulatory milestones this year, including a potential NDA filing. I look forward to working with Don, Jean and the Gloucester team to accomplish these near-term objectives while continuing to build value with Romidepsin in a range of oncology indications.”
Prior to Gloucester, Dr. Colowick was President, Oncology of Geron Corporation, where he was responsible for the strategic and operational activities of the company’s oncology programs. Prior to joining Geron, Dr. Colowick was the Chief Medical Officer at Threshold Pharmaceuticals. Previously, he held various management positions with Amgen, Inc., most recently serving as Vice President of European Medical Affairs, where he was responsible for products in multiple therapeutic areas, including hematology-oncology, nephrology and internal medicine. While at Amgen, Dr. Colowick led the team responsible for the successful registration and launch of Aranesp® in the US, EU and Australia. Dr. Colowick was a clinical and research fellow in hematology-oncology at Harvard University and the Brigham and Women’s Hospital/Dana Farber Cancer Institute. He holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University and an M.P.H from Harvard University.
Romidepsin is a novel histone deacetylase inhibitor. Gloucester is currently conducting a pivotal phase II study with romidepsin for patients with peripheral T-cell lymphoma (PTCL). The company recently completed its pivotal phase II study with romidepsin for patients with cutaneous T-cell lymphoma (CTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which include CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL and PTCL has also been designated by the FDA. Romidepsin is also in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the company.
About Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. is a privately held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com, or call 888-GPI-CTCL (888-474-2825).
Source: Gloucester Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.